Date | Price Target | Rating | Analyst |
---|---|---|---|
6/14/2023 | $19.00 → $4.00 | Buy → Hold | Jefferies |
4/20/2023 | $7.00 | Buy → Hold | Societe Generale |
4/19/2023 | $7.00 | Overweight → Neutral | JP Morgan |
3/16/2023 | $13.00 → $7.00 | Outperform → Market Perform | TD Cowen |
4/12/2022 | $14.00 | Overweight → Equal-Weight | Morgan Stanley |
3/24/2022 | $30.00 → $19.00 | Neutral → Buy | UBS |
2/17/2022 | $35.00 → $27.00 | Outperform | Credit Suisse |
1/18/2022 | $25.00 | Hold → Buy | Societe Generale |
Jefferies downgraded Mytheresa from Buy to Hold and set a new price target of $4.00 from $19.00 previously
Societe Generale downgraded Mytheresa from Buy to Hold and set a new price target of $7.00
JP Morgan downgraded Mytheresa from Overweight to Neutral and set a new price target of $7.00
6-K/A - MYT Netherlands Parent B.V. (0001831907) (Filer)
6-K - MYT Netherlands Parent B.V. (0001831907) (Filer)
6-K - MYT Netherlands Parent B.V. (0001831907) (Filer)
Double-digit Net Sales Growth in H2 of FY24 with +14% and +10% for Q4 FY24 compared to prior year periods Continued US Market Growth with +25% in full FY24 and Net Sales share of the US further expanding to 20% Exceptional Customer Economics through strong increase in average GMV per Top Customers by +4.6% as well as continued growth of Top Customer base with +3.4% in Q4 FY24 Significantly Increased Profitability levels in H2 of FY24 with adjusted EBITDA margin of 4.3% vs. 1.7% in H1 of FY24 and vs. 2.3% in H2 of FY23 Strong Customer Satisfaction with industry-leading Net Promoter Score of 83.0% in Q4 of FY24 Strong Increase of Average Order Value (AOV) to a new record of €703 in
MYT Netherlands Parent B.V. (NYSE:MYTE) ("Mytheresa") today announced the date for the release of its fourth quarter and full fiscal year 2024 ended June 30, 2024 financial results. Fourth Quarter and Full Fiscal Year 2024 Earnings Call and Webcast Mytheresa will release fourth quarter and full fiscal year 2024 financial results before the U.S. market open on September 12, 2024. A conference call to discuss its results will follow at 8:00am Eastern Time that same day. Those wishing to participate via webcast should access the call through Mytheresa's Investor Relations website at https://investors.mytheresa.com. Those wishing to participate via the telephone may dial in at +1 (800) 71
MYT Netherlands Parent B.V. (NYSE:MYTE) ("Mytheresa"), the parent company of Mytheresa Group GmbH, today announced that Michael Kliger, CEO, and Martin Beer, CFO, will be attending the following investor conferences: Morgan Stanley 2nd Annual Luxury Conference in Paris TD Cowen 8th Future of the Consumer Conference in New York City Michael Kliger will be present at the Morgan Stanley Annual Luxury Conference in-person in Paris on Wednesday, May 22, 2024 with a presentation at 15:00h CET on that day. Martin Beer will be present at the Cowen Future of the Consumer Conference in-person in New York on Tuesday, June 4 and Wednesday, June 5, 2024 with a Fireside Chat at 11:30am ET on J
Double-digit Net Sales Growth in H2 of FY24 with +14% and +10% for Q4 FY24 compared to prior year periods Continued US Market Growth with +25% in full FY24 and Net Sales share of the US further expanding to 20% Exceptional Customer Economics through strong increase in average GMV per Top Customers by +4.6% as well as continued growth of Top Customer base with +3.4% in Q4 FY24 Significantly Increased Profitability levels in H2 of FY24 with adjusted EBITDA margin of 4.3% vs. 1.7% in H1 of FY24 and vs. 2.3% in H2 of FY23 Strong Customer Satisfaction with industry-leading Net Promoter Score of 83.0% in Q4 of FY24 Strong Increase of Average Order Value (AOV) to a new record of €703 in
MYT Netherlands Parent B.V. (NYSE:MYTE) ("Mytheresa") today announced the date for the release of its fourth quarter and full fiscal year 2024 ended June 30, 2024 financial results. Fourth Quarter and Full Fiscal Year 2024 Earnings Call and Webcast Mytheresa will release fourth quarter and full fiscal year 2024 financial results before the U.S. market open on September 12, 2024. A conference call to discuss its results will follow at 8:00am Eastern Time that same day. Those wishing to participate via webcast should access the call through Mytheresa's Investor Relations website at https://investors.mytheresa.com. Those wishing to participate via the telephone may dial in at +1 (800) 71
Excellent top-line growth with Net Sales growing +17.6% and GMV +14.7% in Q3 FY24 Mytheresa US business outperformance with record GMV growth of +41.6% and +48.3% growth of US Top Customers in Q3 FY24 Continued strong global Top Customers growth with number of Top Customers growing by +17.0% in Q3 FY24 Significant growth of Average Order Value LTM increasing by +8.0% to a record high of €692 in Q3 FY24 Significantly improved profitability on adjusted EBITDA level during the quarter as compared to the prior year period MYT Netherlands Parent B.V. (NYSE:MYTE) ("Mytheresa" or the "Company"), today announced financial results for its third quarter fiscal year 2024 ended March 31
Shares of Ovid Therapeutics Inc (NASDAQ:OVID) dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Takeda Pharmaceutical Co Ltd (NYSE:TAK) announced topline data from its SKYLINE and SKYWAY Phase 3 studies of Soticlestat (TAK-935) for the treatment of Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS). AMMO shares dipped 19.1% to $2.0306 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers Interactive Strength Inc. (NASDAQ:TRNR) shares climbed 148% to $7.07 after dipping 19% on Friday. Mustang Bio, Inc. (NASDAQ:MBIO) shares jumped 145% to $0.32 after the company announced safety and efficacy da